7-OH & Kratom Dependence Treatment in Connecticut

Connecticut does not impose a total ban on every product containing naturally occurring 7-OH. However, products sold or delivered in Connecticut cannot contain more than 0.5 milligrams of 7-OH per gram or more than 1 milligram per serving.

Connecticut also prohibits kratom products containing synthetic 7-OH, synthetic mitragynine or other synthetically derived kratom compounds. Many concentrated tablets, gummies, shots and similar products may not comply with these requirements.

Connecticut does not have a total statewide ban on compliant kratom products for adults age 21 and older.

Anyone under 21 is prohibited from purchasing or possessing kratom, kratom extracts or kratom products. Products must also comply with Connecticut's concentration, formulation, labeling, display and retail requirements.

Connecticut has not enacted a total ban on all naturally occurring 7-OH, but it already prohibits synthetic 7-OH and restricts the amount permitted in kratom products.

Separately, the DEA announced its intent to temporarily place 7-OH above a specified threshold into Schedule I under federal law. As of the August 6, 2026 legal review date, the Federal Register contained the notice of intent, but the final temporary scheduling order had not yet been published. Federal status could change shortly after publication of this page.

Consider speaking with a medical provider before your supply ends, especially if you use 7-OH every day or experience withdrawal symptoms between doses.

Tell the provider the exact product you use, the amount per dose, how frequently you take it and whether you use any other substances. Avoid automatically replacing 7-OH with another concentrated or unregulated product.

There is no universal over-the-counter replacement for 7-OH.

The appropriate treatment depends on whether you were using it for pain, energy, anxiety, opioid withdrawal, cravings or to prevent withdrawal from 7-OH itself. A medical provider can evaluate the underlying reason and recommend appropriate treatment options.

Possible symptoms include restlessness, sweating, chills, body aches, nausea, stomach discomfort, diarrhea, difficulty sleeping, anxiety, irritability, low mood and cravings.

Symptoms can vary depending on the product, concentration, dose, frequency of use, length of use and other substances being taken.

There is no single established timeline that applies to every patient.

The duration and severity of withdrawal may be influenced by how much you use, how often you take it, how long you have used it, the concentration of the product, your health history and whether other substances are involved.

A provider can offer more individualized guidance after completing an evaluation.

Some people may be able to receive outpatient or telehealth support, while others require in-person detoxification or a higher level of care.

The safest setting depends on your level of dependence, withdrawal history, medical conditions, mental-health symptoms, use of other substances and available support at home.

Do not attempt to manage severe withdrawal or serious medical symptoms without professional help.

Eligible patients located in Connecticut may receive a confidential online medical evaluation from DevotedDOc when an appropriately licensed provider is available.

The provider will determine whether telehealth care is appropriate or whether you need in-person treatment or a higher level of support.

A licensed provider may consider buprenorphine/naloxone in selected cases involving opioid-like dependence or opioid use disorder.

Suboxone is not automatically appropriate for everyone using 7-OH. A medical evaluation is required, and receiving an appointment does not guarantee that a particular medication will be prescribed.

Not everyone requires residential rehabilitation.

Depending on your symptoms and treatment needs, care may be provided through telehealth, outpatient medical treatment, counseling, intensive outpatient treatment, medically supervised detoxification or residential care.

A clinical evaluation helps determine the safest and most appropriate level of support.

7-hydroxymitragynine — abbreviated 7-OH, 7OH or 7-HMG — is one of several alkaloids that occur naturally in the kratom plant, Mitragyna speciosa, though only in small amounts in raw kratom leaf.

7-OH is not the same as kratom itself. Kratom refers to the whole botanical material, which contains many alkaloids beyond 7-OH. Commercial 7-OH tablets, gummies, shots and similar products may contain added, isolated or enhanced concentrations that are substantially different from traditional kratom leaf.

Regular use may lead to tolerance and physical dependence. A person who has become dependent may experience withdrawal symptoms, cravings or difficulty reducing use.

Needing more of the product to achieve the same effect or taking it mainly to avoid feeling sick may be signs that medical support is needed. FDA has documented cases of substance-use disorder, tolerance, cravings and withdrawal associated with kratom products.

These are synthetically derived compounds related to 7-hydroxymitragynine. Connecticut prohibits synthetically derived kratom compounds in products sold in the state. The DEA has also issued notices of intent to place these three substances in Schedule I under federal law. Federal status may have changed since this page's August 6, 2026 legal review date.

DevotedDOc provides private medical care through secure telehealth appointments.

Patient information is handled according to applicable privacy requirements and DevotedDOc's published privacy practices.